REVIEW

Activin/Nodal signalling in stem cells

Siim Pauklin and Ludovic Vallier*

ABSTRACT

Activin/Nodal growth factors control a broad range of biological processes, including early cell fate decisions, organogenesis and adult tissue homeostasis. Here, we provide an overview of the mechanisms by which the Activin/Nodal signalling pathway governs stem cell function in these different stages of development. We describe recent findings that associate Activin/Nodal signalling to pathological conditions, focusing on cancer stem cells in tumorigenesis and its potential as a target for therapies. Moreover, we will discuss future directions and questions that currently remain unanswered on the role of Activin/Nodal signalling in stem cell self-renewal, differentiation and proliferation.

KEY WORDS: Activin, Cell cycle, Differentiation, Nodal, Pluripotency, Stem cells

Introduction

Activin and Nodal are members of the transforming growth factor β (TGFβ) superfamily of morphogens, which comprises at least 42 members in humans and includes inhibins, TGFβs, bone morphogenetic proteins (BMPs), growth and differentiation factor (GDF), myostatin, Müllerian-inhibiting substance and others (Oshimori and Fuchs, 2012a). The TGFβ superfamily is found in metazoans and arose alongside multicellularity, with the Nodal, Activin and BMP families considered as the evolutionarily most ancient family members (Pang et al., 2011). Nodal was identified in the mouse through a retroviral insertion mutagenesis screen (Robertson et al., 1986), and indicated a distinct expression in the node region while causing a striking defect in gastrulation upon its disruption (Conlon et al., 1991, 1994; Zhou et al., 1993). The Nodal subfamily is present in most metazoans except for Drosophila and C. elegans (Rebagliati et al., 1998). Activin was discovered in the 1980s as a gonadal protein that induced follicle-stimulating hormone (FSH) release, but since then has been found to be expressed in many different cell types at nearly all stages of development (Vale et al., 1986). Nodal and Activin ligands can both signal through the same receptors and effectors in order to regulate transcription. In many cases, the effects of Nodal and Activin-mediated signalling are indistinguishable; hence, they are referred to as the Activin/Nodal pathway. Similarly, as discussed further below, the Activin/Nodal and TGFβ pathways share the downstream effectors Smad2 and Smad3. Thus, these pathways are often considered to have similar functions even though their tissue expression pattern is often different.

Nodal was one of the first genes knocked out in mice (Collignon et al., 1996; Zhou et al., 1993), and its function in early development has been broadly studied in different model organisms. Of particular relevance, genetic studies in the mouse have established that Nodal signalling is necessary at the early epiblast stage during implantation, in which the pathway functions to maintain the expression of key pluripotency factors as well as to regulate the differentiation of extra-embryonic tissue. Activins, dimers of different subtypes of Inhibin β, are also expressed in pre-implantation blastocyst but not in the primitive streak (Albano et al., 1993; Feijen et al., 1994). However, genetic studies have shown that Inhibin βs are not necessary for early development in the mouse (Lau et al., 2000; Matzuk, 1995; Matzuk et al., 1995a,b). Combined gradients of Nodal and BMP signalling within the primitive streak control endoderm and mesoderm germ layer specification and also their subsequent patterning whilst blocking neuroectoderm formation (Camus et al., 2006; Mesnard et al., 2006). Following implantation, a gradient of Nodal signalling defines the proximal-distal axis, which in turn establishes the anterior-posterior axis of the developing embryo (Arnold and Robertson, 2009). At later stages of embryogenesis, Nodal governs left-right axis asymmetry and further patterning of the neural and gut tubes (Brennan et al., 2002; Sajioh et al., 2003; Schier et al., 1997). In parallel, a vast number of studies have shown that Activin/Nodal morphogens regulate a range of cellular processes, including cell cycle progression, progenitor proliferation/differentiation during organogenesis (Brennan et al., 2001; Feldman et al., 1998; Gritsman et al., 2000) and adult tissue homeostasis in some tissues (Strizzi et al., 2012). Of note, deregulation of TGFβ and Activin/Nodal signalling pathways also plays a prominent role in tumorigenesis and metastasis (Massagué, 2008), which might be related to the function of these signalling pathways in embryonic development.

Consistent with its role in the epiblast stage, Activin/Nodal signalling has recently been shown to maintain pluripotency in human pluripotent stem cells (hPSCs) (Vallier et al., 2004) and also in mouse epiblast stem cells (mEpiSCs) (Brons et al., 2007). This function is achieved through complex interactions with pluripotency factors including Nanog (Vallier et al., 2009a), and also by cross-talk with cell cycle-related mechanisms (Pauklin and Vallier, 2013).

The near-ubiquitous activity of Activin, Nodal and TGFβ during development, and their function in tissues containing well-established adult stem cells, tentatively suggest that the function of Activin/Nodal signalling in self-renewal could be conserved across embryonic and tissue-specific adult stem cells.

In this Review, we discuss the role of Activin/Nodal signalling pathways in mediating pluripotency and early cell fate decisions, embryonic development, adult tissue homeostasis and tumorigenesis, with the aim to identify common stem cell-related mechanisms. We also briefly discuss the function of TGFβ signalling in these processes and the similarities with its sibling pathway Activin/Nodal.

Activin/Nodal signalling pathway

Ligands and receptors

Nodal is synthesised as precursor, with a large pro-domain and a mature carboxy-terminal domain, which is cleaved by the
pro-protein convertases Spc1 and Spc4 (Constam and Robertson, 2000) to generate an active protein. Nodal forms homomeric dimers held together by disulphide bonds. There is only one Nodal gene in mouse, human and birds (Zhou et al., 1993), three in zebrafish (Erter et al., 1998; Feldman et al., 1998; Rebagliati et al., 1998; Sampath et al., 1998) and five in Xenopus (Jones et al., 1995; Joseph and Melton, 1997). By contrast, Activins are formed by homodimers or heterodimers of Inhibin subunits (βα, ββ, βc, βe), which are also held together by a disulphide bond. The combination of different Inhibin subunits results in a diversity of Activins, with Activin A (Inhibin βα dimer), B (Inhibin ββ dimer) and AB (dimer of Inhibin βα and ββ) being the most extensively studied and the evolutionarily most conserved. Genetic studies have shown that Inhibin βα and ββ subunits have different functions in late development and adult tissues (Matzuk, 1995; Matzuk et al., 1995a,b), whereas Inhibin βc and βe do not appear necessary for normal development and homeostasis (Lau et al., 2000).

Activins and Nodal exert their biological effects by interacting with two types of transmembrane receptors (types I and II), which have intrinsic serine/threonine kinase activities in their cytoplasmic domains (Fig. 1, Table 1) (Wrana et al., 1994). Activin/Nodal bind to type II Activin receptors (ActRII/IIB), leading to the recruitment,
Table 1. Main components of the Activin/Nodal signalling pathway

<table>
<thead>
<tr>
<th>Pathway component</th>
<th>Signalling pathway</th>
<th>Gene name/symbol</th>
<th>Binding partners</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ligands</td>
<td>Nodal</td>
<td>Nodal (human, mouse, bird), cyclops, squint, southpaw (fish), *nr1, *nr2, *nr4, *nr5, Gdf1 (mouse), Gdf3 (mouse)</td>
<td>Nodal pathway inhibitors</td>
<td>Nodal-related TGFβ ligands, activate signalling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vgf1 (frog, fish, bird) activin bA, bB, bC, bE (human)</td>
<td>Follistatin</td>
<td>Ligand, activates signalling</td>
</tr>
<tr>
<td>Receptors</td>
<td>Nodal</td>
<td>ALK4, ALK7</td>
<td>ActRII, ActRIIB, Co-receptors ALK4, ALK7</td>
<td>Type I serine-threonine kinase receptor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ActRII, ActRIIB</td>
<td>ActRII ALK4</td>
<td>Type II serine-threonine kinase receptors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALK4</td>
<td>ActRII ALK4</td>
<td>Type I serine-threonine kinase receptor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALK5</td>
<td>ActRII ALK5</td>
<td>Type II serine-threonine kinase receptors</td>
</tr>
<tr>
<td>Co-receptors</td>
<td>Nodal</td>
<td>cripto (human), cryptic (mouse) (Cfc1 – Mouse Genome Informatics), one-eyed pinhead (zebrafish), FRL-1/*CR1, *CR2, *CR3 (frog)</td>
<td>ALK4</td>
<td>EGF-CFC co-receptors, necessary for activating Nodal signalling but inhibits Activin signalling</td>
</tr>
<tr>
<td>Inhibitors</td>
<td>Nodal</td>
<td>Lefty1, Lefty2</td>
<td>ActRII</td>
<td>Inhibit Nodal signalling by binding to Nodal receptor and EGF-CFC co-receptors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cer1, Cer2, Gremlin Follistatin</td>
<td>Nodal</td>
<td>Inhibit signalling by binding to Nodal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follistatin</td>
<td>Actinin</td>
<td>Inhibits signalling by binding to Activins</td>
</tr>
<tr>
<td>Intracellular transduction proteins</td>
<td>Nodal, Actinin</td>
<td>Smad2, Smad3</td>
<td>Smad3, Smad4</td>
<td>Smad2, Smad4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smad4</td>
<td>Smad2, Smad3</td>
<td>Co-Smad, helps transporting Smad2 and Smad3 into the nucleus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smad7</td>
<td>Smad2, Smad3</td>
<td>Inhibitory-Smad, blocks the activity of Smad2 and Smad3</td>
</tr>
</tbody>
</table>

phosphorylation and activation of type I Activin receptors (Activin receptor-like kinases, or ALKs, including ALK1-7), in particular of ALK4, also known as ActRIIB (Tsuchida et al., 2004). The serine/threonine kinase receptors ActRII/IIIB and ALK4/7 then trigger the phosphorylation of the Smad transcription factors, discussed further below (Wrana et al., 1994). Of note, TGFβ members bind to a different set of receptors TGFBR1 and TGFBR2 (or ALK5) (Fig. 1).

Activin/Nodal often act as morphogens (Box 1), and their activity is regulated by multiple mechanisms, including extracellular antagonists (Lefty1/2, Cerberus, Follistatin) and agonists (CRIPTO1), processing enzymes (Spc1, Spc4), intracellular molecules (Smad6/7, TMEPA1) and co-regulators (FoxH1), as well as proteins involved in receptor trafficking and miRNAs (Schier, 2009) (Fig. 1, Table 1). These mechanisms coordinate the activity and tissue specificity of this important signalling pathway in different cellular and developmental contexts.

**Smads and Smad-binding transcriptional regulators**

The Activin/Nodal pathway exerts its effects by orchestrating transcriptional networks controlling gene expression and downstream cellular processes. This is mediated by three classes of Smad proteins: the receptor-regulated R-Smads, the common mediator Co-Smads and the inhibitory I-Smads. Smad1/5/8 signalling is activated by other TGFβ superfamily members, such as BMP, whereas Activin/Nodal and TGFβ signalling pathways are specifically mediated through Smad2 and Smad3 (R-Smads), Smad4 (Co-Smad) and Smad7 (I-Smad) (Fig. 1, Table 2) (Shi and Massagué, 2003). Smad2 and Smad3 form a complex (Smad2/3) in the cytoplasm, which interacts with Smad4 after phosphorylation and then moves into the nucleus. R-Smads and Co-Smads contain a highly conserved amino-terminal Mad homology MH1 domain, a weakly conserved linker region and the carboxyl-terminal MH2 domain (Fig. 2) (Massagué et al., 2005). The MH1 domain mediates the binding of Smads to DNA and their interaction with other transcription factors. The MH2 domain is involved in transcriptional activation, interaction between Smad proteins or their transmembrane receptors, as well as their binding to various transcription factors (Wrana, 2000). Phosphorylation of the linker region of Smads affects their stability and their movement to the nucleus, thus regulating the abundance of Smad proteins on the chromatin (Kretzschmar et al., 1999). The linker domain also mediates Smads proteasome-mediated degradation through interaction with Smurf proteins (Zhang et al., 2001). In addition, Smad2/3 is activated by receptor-mediated phosphorylation and is inhibited by phosphatases such as PPM1A (Lin et al., 2006). Dephosphorylated Smad2/3 is then recognised by RANBP3 and exported out of the nucleus (Dai et al., 2009).

Smad4 and the R-Smads, with the exception of Smad2, bind directly to DNA, although with low affinity and low specificity (Ross and Hill, 2008). Smad3 and Smad4 recognise a Smad-binding element (SBE), which consists of AGAC or its reverse complement. In order to achieve higher affinity and selectivity for DNA-binding sites, Smad proteins can also associate with various tissue-specific transcription factors (see Table 2), which mediate a range of processes, including pluripotency (Mullen et al., 2011; Suzuki et al., 2006; Vallier et al., 2009a), mesendoderm specification (Teo et al., 2011), muscle cell (Mullen et al., 2011; Suzuki et al., 2006; Vallier et al., 2009a), mesendoderm specification (Teo et al., 2011), muscle cell...
Box 1. Spatio-temporal effects of Activin/Nodal concentration gradients

Activin and Nodal ligands have short-range effects on nearby cells as well as long-range effects during development (Smith et al., 2008). As an example of a short-range effect, Nodal is positively auto-regulated by Smad2/3 via an asymmetric enhancer located in its first intron (Adachi et al., 1999) and via an upstream left-side-specific enhancer (Saigoh et al., 2003). For long-range effects, Nodal is secreted by node cells and can activate its target genes in distant cells of the lateral plate mesoderm (Öki et al., 2007). The Nodal effect is also dose-dependent, as low levels of Nodal are sufficient to induce target genes such as brachyury/β, whereas goosecoid is only activated by high levels of Nodal during mesoderm and endoderm patterning (Gurdon and Bourillot, 2001; Schier and Talbot, 2005). Nodal forms concentration and activity gradients during development that provides positional information, which ultimately directs the cell fate decision of the target cells (Brennan et al., 2001). This is particularly evident in the formation of the vegetal-animal axis (Faure et al., 2000; Gritsmann et al., 2000; Harvey and Smith, 2009). The time of Nodal signalling is also important for cell fate decisions, as duration of Nodal signalling has different effects and results in the generation of different cell types (Hagos and Dougan, 2007). Of note, the spatiotemporal effects of Activin/Nodal concentration gradients have yet to be taken into account in vitro. Indeed, current protocols of differentiation use large doses of Activin and two-dimensional culture systems, which are likely to bypass the regulation of gradient formation. This could result in the absence of positional information during in vitro specification and represents one of the challenges for generating specific cell types from hPSCs.

Table 2. Known binding partners of Smad2/3 and their function

<table>
<thead>
<tr>
<th>Signalling pathway</th>
<th>Smad family member</th>
<th>Tissue type</th>
<th>Interacting protein</th>
<th>Function</th>
<th>Target loci</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activin/ Nodal</td>
<td>Smad2, Smad3</td>
<td>Human pluripotent stem cell</td>
<td>NANOG, OCT4, P300 (EP300 – Human Gene Nomenclature Committee)</td>
<td>Maintenance of pluripotency</td>
<td>Pluripotency genes (OCT4, NANOG)</td>
</tr>
<tr>
<td></td>
<td>Smad2, Smad3</td>
<td>Human pluripotent stem cell</td>
<td>SnO2 (SKL – Human Gene Nomenclature Committee)</td>
<td>Transcriptional activation by histone acetylation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smad2, Smad3</td>
<td>Mesoderm</td>
<td>EOMES, FOXH1, GSC, Mixer</td>
<td>Inhibition of differentiation</td>
<td>Endoderm genes</td>
</tr>
<tr>
<td>TGFβ</td>
<td>Smad3</td>
<td>Myotube</td>
<td>MYOD1, PU.1, FOXO3</td>
<td>Myocyte identity, Pro-B-cell maturation, Cell cycle inhibition</td>
<td>Myocyte genes, B-cell-specific genes, CDK inhibitors p15Ink4b (CDKN2B – Human Gene Nomenclature Committee; p21Cip1 (CDKN1A – Human Gene Nomenclature Committee)</td>
</tr>
<tr>
<td></td>
<td>Smad2, Smad3, Smad4</td>
<td>Keratinocyte</td>
<td>E2F4/5</td>
<td>Cell cycle inhibition</td>
<td>MYC</td>
</tr>
<tr>
<td></td>
<td>Smad2, Smad3, Smad4</td>
<td>Epithelial cells</td>
<td>CEBPB</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smad2, Smad3, Smad4</td>
<td>Epithelial cells</td>
<td>SP1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smad2</td>
<td>Epithelial cells</td>
<td>ATF3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Tissue specificity is indicated where known.
hiPSCs) into derivatives of the three germ layers. This confirms that these pluripotent cells rely on the same set of signalling pathways, including Activin/Nodal, to control their cell fate decisions (Vallier et al., 2009b,c). Taken together, these reports lead to the conclusion that hPSCs and EpiSCs share a similar pluripotency state characterised by their dependency on Activin/Nodal signalling. Nevertheless, hESCs and EpiSCs are not strictly identical: contrary to EpiSCs, hESCs express pre-implantation markers such as REX1 (Chan et al., 2009) and not post-implantation markers such as FGF5 (Vallier et al., 2004), and also can exhibit X activation, indicative of pre-implantation stages (Lengner et al., 2010; Tomoda et al., 2012). These observations could underline species divergence. Indeed, human and mouse seem to use different signalling pathways during their early development (Nichols et al., 2001). Therefore, Activin/Nodal signalling could have an early function in human pre-implantation embryos, which could be masked by redundant mechanisms in the mouse embryo between TGFβs and Activin/Nodal signalling (Sato et al., 2003). Basic studies on human embryos, using recent advances in single-cell gene expression profiling, could be advantageous to confirm this hypothesis. These results would be essential to develop new culture systems for the derivation of inner cell mass (ICM)-like ESCs and help to dissipate the controversy concerning the existence of ground-state hESCs (Gafni et al., 2013). FGF is also necessary to maintain the expression of pluripotency markers in hESCs (Levenstein et al., 2006). Nevertheless, chemical inhibition of FGF receptors can be rescued by increasing the quantity of exogenous Activin, whereas absence of Activin signalling cannot be reversed by a high dose of FGF (Vallier et al., 2005). Therefore, FGF signalling appears to synergise with Activin to regulate pluripotency rather than to act independently (Fig. 3). This mechanism could involve SOX2, as this gene is regulated in hPSCs by ERK2, an effector of the FGF signalling (Yu et al., 2011). Thus, FGF might support the function of Activin/Nodal signalling in hESCs by activating a complementary transcriptional network ( Göke et al., 2013).

![Functional domains and sites of post-translational modifications on Smad2/3 and Smad4 proteins](image-url)

**Fig. 2.** The functional domains and sites of post-translational modifications on Smad2/3 and Smad4 proteins. Smad proteins contain three distinct functional domains: the N-terminal MH1 domain (blue), the middle LINKER domain (green) and the C-terminal MH2 domain (pink). Smad2/3 and Smad4 proteins not only act as important effectors for the Activin/Nodal signalling pathway but interconnect various other signalling pathways that induce post-translational modifications on specific residues of Smad proteins. Coloured circles, phosphorylation sites; coloured stars, PIAS ubiquitylation sites; coloured squares, ubiquitylation sites; coloured diamonds, p300 interaction sites. NLS, nuclear localisation signal; NES, nuclear export signal; DNA, DNA-binding region.
Although Activin/Nodal signalling is crucial to maintain pluripotency in the mouse epiblast and derived cells, the function of this signalling pathway in murine ESCs (mESCs) remains unclear. Indeed, overexpression of Smad6/7 in mESCs grown in foetal calf serum only decreases their proliferation, thus suggesting that Activin/Nodal/TGFβ are not required for their pluripotency (Ogawa et al., 2007). Furthermore, genetic studies in the mouse have not revealed any function for Activin/Nodal signalling in embryos at pre-implantation stages. Despite these observations, some evidence suggests a possible role for Activin/Nodal signalling in mESCs. Chromatin immunoprecipitation analyses combined with deep sequencing (ChIP-Seq) analyses showed binding of the Smad2/3 complex to the Oct4 (Pou5f1 – Mouse Genome Informatics) locus in mESCs grown in the absence of serum, whereas chemical inhibition of ALK4/7 induces differentiation toward trophectoderm (Lee et al., 2011). Further investigations are therefore necessary to define more clearly the importance of Activin/Nodal signalling in mESCs.

Interestingly, mESCs appear to rely on fundamentally different mechanisms of self-renewal when compared with hESCs. A popular model for this implies that mESC pluripotency does not require an inductive signalling pathway, but rather that it is the result of a passive balance between different signalling pathways repressing differentiation (i.e. LIF blocks mesendoderm, whereas BMP4 blocks neuroectoderm) or the total absence of inductive signals of differentiation (2i+LIF system) (Ying et al., 2003, 2008). Accordingly, self-renewal of mESCs can be stabilised by chemically inhibiting GSK3β and the ERK kinase pathway in the absence of exogenous growth factors, thus confirming that extracellular stimuli are not required for pluripotency in mESCs.

The situation is fundamentally different in hESCs, in which Activin plays a direct and inductive role not only in blocking neuroectoderm differentiation but also in maintaining the expression of key pluripotency factors, such as OCT4 and NANOG (Vallier et al., 2009a). Smad2/3 also directly interact with OCT4 and NANOG across a range of promoters and might
be necessary for the activity of these factors. Consequently, the Smad2/3 complex is fully integrated into the transcriptional network characterising hESCs, and loss of Smad2/3 transcriptional activity consistently results in differentiation (Vallier et al., 2009a). The use of chemical inhibitors remains largely inadequate to maintain pluripotency in hESCs, underscoring once again that the pluripotency states of hESCs and mESCs are conceptually different. Interestingly, the attempts to generate ground-state-like hESCs directly from embryos include an exogenous source of TGFβ, and chemical inhibition of ALK4/7 induces differentiation of the resulting pluripotent stem cells (Gafni et al., 2013; Theunissen et al., 2014). This suggests that the role of TGFβ in the pre-implantation human embryo has been underestimated and deserves further investigation.

Importantly, the Smad2/3 complex can be found on a range of mesendoderm genes, even in undifferentiated hESCs or in EpiSCs; this binding could explain why transcripts of differentiation markers can be detected either by qPCR or gene expression array in these cell types (Brown et al., 2011). Indeed, the presence of the Smad2/3 complex on these promoters could result in transcriptional leakiness, producing significant amounts of these transcripts that are usually associated with differentiated cells. This phenomenon has little or no phenotypic effect, as the proteins of the corresponding genes cannot be detected. Interestingly, a broad range of these genes display bivalent histone marks (positive and negative), which have been shown to prime transcription in stem cells (Pan et al., 2007). Activin/Nodal signalling via Smad2/3 could therefore maintain pluripotency, but also enable hESCs to prime the expression of tissue-specific differentiation genes, thus allowing rapid cell fate choices. This supports the concept that hESCs might represent a primed state of pluripotency as opposed to the ground state observed in mESCs. However, mESCs grown in serum are also considered as the true inducer of differentiation. WNT and BMP signalling also plays a key function in controlling Activin/Nodal signalling, suggesting that the specificity of Activin/Nodal signalling might be defined by the genomic location of its binding partners (Brown et al., 2011).

Interestingly, the transcriptional networks downstream of Smad2/3 and NANOG, as well as OCT4, significantly overlap in hESCs, which further indicates a potential interaction between these factors. Co-immunoprecipitation analyses have shown that Smad2/3 and NANOG could be part of the same protein complex in hESCs, and that they cooperate to orchestrate the transcriptional network characterising hPSCs (Vallier et al., 2009a). Further studies have also revealed an interaction between Smad2/3 and EOMES upon endoderm differentiation, suggesting that the specificity of Activin/Nodal signalling is not to self-renew but to generate the necessary cells for normal development and organogenesis.

**Activin/Nodal signalling as inducer of endoderm differentiation**

Despite its essential activity in maintaining pluripotency, Activin/Nodal signalling is also required for endoderm differentiation (Arnold and Robertson, 2009; D’Amour et al., 2005; Kubo et al., 2004). Accordingly, inhibition of Activin/Nodal signalling blocks the expression of endoderm markers and promotes the expression of mesoderm markers in the presence of BMP4 in vitro (Kubo et al., 2004) and in a broad number of species (Chen and Schier, 2001).

Activin/Nodal signalling achieves this function by interacting with other key signalling pathways, especially BMP and WNT (Tam and Loebel, 2007). The molecular mechanisms involved in this cross-talk among pathways have been particularly well studied in amphibians and fish, in which it has been shown that BMP-Smad1/5/8 interact with mesoderm regulators such as Brachyury to repress endoderm markers, induced by Nodal-Smad2/3 (Garnett et al., 2009; Messenger et al., 2005; Morley et al., 2009). At the same time, WNT signalling also plays an essential function in mesendoderm specification by controlling the expression of Nodal and its co-receptor Cripto during gastrulation (Tam and Loebel, 2007).

Importantly, genome-wide analyses performed on hESCs differentiating into endoderm have shown that the Smad2/3 complex directly controls the transcriptional activity of a broad number of endoderm genes (Brown et al., 2011). Thus, the transcriptional network driving endoderm specification is ultimately orchestrated by Smad2/3 and its partners (Table 2, Fig. 3). BMP and WNT could be required only to initiate and to stabilise this network, respectively. Accordingly, BMP plays a crucial role in vitro to block the protective activity of Activin/Nodal signalling on pluripotency and to promote the induction of endoderm specification (Sakaki-Yumoto et al., 2013). Furthermore, WNT/β-catenin interacts with Smad2/3 target genes such as SOX17 to activate the expression of other genes such as FOXA2 (Sinner et al., 2004), which are essential for endoderm patterning and organogenesis. Further genome analyses detailing the target genes downstream of Smad1/5/8 and β-catenin could help to further uncover the nature of the molecular cross talk between Activin/Nodal, WNT and BMP.

The mechanisms by which Activin/Nodal signalling maintains pluripotency while inducing endoderm differentiation also remain to be fully elucidated, and several studies have started to reveal some important regulatory mechanisms. ChIP-Seq analyses showed that the location of Smad2/3 binding in the genome changes upon endoderm differentiation, suggesting that the specificity of Activin/Nodal signalling might be defined by the genomic location of its binding partners (Brown et al., 2011).

The model proposed above also suggests that inhibition of NANOG expression is necessary to enable Smad2/3 to interact with EOMES and thus, to redirect the activity of Activin/Nodal signalling towards endoderm formation. This inhibition is likely to be induced by one or more signalling pathways, which could be considered as the true inducer of differentiation. WNT and BMP signalling are the most likely candidates: their function in endoderm and mesoderm specification has been studied in amphibians, fish and mouse, and they are often included in the cocktail of growth factors used to generate endoderm from hPSCs in vitro. Importantly, Activin/Nodal signalling cannot fulfill this function alone, as even high doses of exogenous Activin/Nodal only reinforce the expression of pluripotent markers in hPSCs (Vallier et al., 2005).

In addition to its role in primitive streak and mesoderm induction, BMP4 has also been shown to induce the differentiation of hESCs toward extra-embryonic tissue, and this effect can be blocked by Activin/Nodal (Vallier et al., 2009c). Furthermore, Smad1/5/8 and Smad2/3, which mediate BMP and Activin/Nodal signalling, respectively, bind to the same region of the Nanog promoter, suggesting that BMP4 and Activin/Nodal might compete to modulate the expression of key pluripotency markers (Xu et al., 2008). BMP4 can also induce differentiation by activating the expression of EOMES, which then feeds into the Smad2/3 transcriptional network and ultimately represses the expression of NONOG (Teo et al., 2011).

WNT signalling also plays a key function in controlling Activin/Nodal signalling, as blocking the PI3K/ERK pathway, and thereby inhibiting GSK3β, are sufficient to induce endoderm differentiation...
of hESCs (Singh et al., 2012). Furthermore, β-catenin and the Smad2/3 complex have been shown to converge on mesendoderm genes to activate their transcriptional activity (Bernardo et al., 2011). Taken together, these reports support the role of WNT in modulating the activity of Activin/Nodal signalling. Nevertheless, the molecular mechanisms by which this synergy takes place remain unknown, and further molecular analyses are necessary to fully understand the cross-talk between Smad2/3 and GSK3β/β-catenin.

Finally, a recent study showed that the Hippo pathway can repress Smad2/3 transcriptional activity on endoderm genes in hESCs, and thus maintain the pluripotent state and block mesendoderm induction (Beyer et al., 2013). However, this mechanism seems to be limited to primitive streak genes such as brachyury/T and is cell culture-dependent, suggesting the existence of additional mechanisms involving inductive signals of differentiation.

Taken together, these observations illustrate how Activin/Nodal signalling is interconnected with other signalling pathways, enabling Smad2/3 to have divergent functions in different cell types (self-renewal versus differentiation) and to control a diversity of biological process within the same cell type. However, the precise function and specificity of Smad2/3 in all these cellular processes remains unclear. Indeed, the model proposed above explains in part that the tissue-specific activity of Smad2/3 is dictated by tissue-specific transcription factors; however, it does not provide the molecular mechanism by which Smad2/3 can interact with so many factors while retaining its specificity of action. Proteomic studies in combination with DNA pull-down methods could help to identify the partners that cooperate with Smad proteins to enact different processes within the same cell, such as the induction of p21 for cell cycle regulation or Sox17 for endoderm specification. These experiments could indicate whether Smad2/3 has a generic function in transcriptional regulation, such as recruiting epigenetic regulators, or whether its function varies in the context of different genes and protein complexes.

Activin/Nodal signalling in adult tissue stem cells

Many organs harbour stem cells that function in tissue maintenance and injury repair. These stem cells replenish specialised cell types throughout development and adult life either by constant cell divisions (e.g. intestinal stem cells) (Li and Clevers, 2010) or by transient activation when needed (e.g. hematopoietic system, hair follicles, mammary glands) (Fuchs, 2009; Lange and Calegari, 2010; Orford and Scadden, 2008). The TGFβ superfamly is involved in self-renewal of adult stem cells in many of these tissues. At high levels, TGFβ usually inhibits cell proliferation in a reversible manner, which might be particularly relevant for the regulation of quiescent state and re-entry of adult stem cells into cell cycle (Massagué, 2012; Tumbar et al., 2004). The mechanism by which TGFβ regulates the cell cycle is described further below. However, the function of Activin/Nodal signalling in the self-renewal or differentiation of adult stem cells is less clear, despite several recent reports suggesting a key role (Cambray et al., 2012; Dunphy et al., 2011; Kadaja et al., 2014). Indeed, the expression of Nodal seems to be limited to certain tissues which undergo considerable remodelling, such as the endometrium, placenta and lactating mammary gland (Quail et al., 2013; Strizzi et al., 2012). This suggests that Nodal might not be involved in the maintenance and specification of many adult stem cells, in contrast to TGFβ, which is more widely expressed. Activin transcripts can be detected in a diversity of tissues, including the pituitary gland, the spleen, the bone marrow and specific parts of the brain (Luìci et al., 2001), but their functions in the cell cycle are yet to be fully investigated. Due to difficulties in the reliable detection of Activins and of Nodal expression, with the possibility of alternative splice variants for the latter (Strizzi et al., 2012), further studies are needed to generalise these observations for a broader range of adult tissues and cell sub-populations in each tissue.

Here, we discuss key examples in which Activin/Nodal signalling is known to be important in adult stem cells, and in which the related TGFβ pathway plays roles that share parallels with, or might shed light on, the functions of Activin/Nodal in these stem cell systems.

Hair follicle stem cells

In adult tissues, there are instances in which Activin signalling has a specific role in maintaining cell ‘stemness’, whereas the function of TGFβ seems to be less important. Indeed, the absence of TGFβ receptor II in mouse skin epithelium does not induce large changes during normal homeostasis (Gusach et al., 2007; Oshimori and Fuchs, 2012b). By contrast, conditional ablation of the Activin receptor type 1B (Alk4 or Acvr1b) causes the degeneration of hair follicles and the formation of cysts with keratinaceous debris. Therefore, despite their similarities and common effectors, TGFβ and Activin signalling appear to control different mechanisms in skin stem cells (Qiu et al., 2011). Accordingly, the self-renewal of hair follicle stem cells and the suppression of epidermal differentiation involve activin B and several other genes that are known to be involved in enhancing Activin signalling, such as Wwp2, S100A4, Sulf2 and Inhhb (Kadaja et al., 2014). The expression of these genes is also controlled by Sox9, a central regulator of hair follicle stem cells. In turn, administration of Activin B can partially compensate for the loss of Sox9 in the hair follicle niche by blocking the premature differentiation of hair follicle stem cells (Kadaja et al., 2014). It would be interesting to determine whether the switch between quiescent and active states of hair follicle stem cells involves specific cell cycle regulators of the INK4 and KIP/CIP family, such as p15 or p21, which are known to be regulated by the cytostatic response of TGFβ signalling in various cells. In addition, the precise effect of Smad2/3 inhibition on cell fate decision in skin stem cells could also reveal novel functions of Activin signalling in their self-renewal and their capacity of differentiation.

Hematopoietic stem cells

In most adult stem cells, such as hematopoietic stem cells or neural stem cells, in which TGFβ signalling plays an important role, the involvement of Activin or Nodal remains unclear. Nevertheless, as TGFβ and Nodal/Activin pathways share receptors and transduction proteins, we will briefly summarise the function of TGFβ signalling in these stem cells and draw parallels between these two closely related pathways.

Adult hematopoietic stem cells (HSCs) reside in the bone marrow among progenitors at different stages of the hematopoietic lineage (Orkin and Zon, 2008; Zhang et al., 2008). The TGFβ signalling pathway has long been implicated in regulating HSC quiescence (Fortunel et al., 2000; Yamazaki et al., 2006). It functions by upregulating the transcription of the cyclin-dependent kinase (CDK) inhibitor p57 and suppressing PI3K/Akt signalling, thus preventing HSC re-entry into the cell cycle (Yamazaki et al., 2006). The latent TGFβ present in the bone marrow seems to be activated by non-myelinating Schwann cells (Yamazaki et al., 2011), and the TGFβ response is mediated by TβRII receptors leading to Smad2/3 phosphorylation.

Of note, HSCs are not a homogenous population of cells but instead can be divided into at least two distinct subtypes that have unique self-renewal properties and exhibit biased differentiation toward different
mature hematopoietic lineages (Dykstra et al., 2007; Lemischka et al., 1986; Sieburg et al., 2006). Interestingly, these HSC subpopulations have distinct cellular responses to TGFβ signalling, which affects their cell cycle state (discussed below) and thus their proliferation capacities (Challen et al., 2010). Therefore, the switch model proposed for pluripotency/endoderm differentiation for Activin/Nodal-Smad2/3 in hPSCs appears to be applicable to BMP4-Smad1/5/8 in HSCs. R-Smads could therefore operate in a similar manner in HSC hematopoietic specification and in hPSC early germ layer differentiation.

Overall, TGFβ signalling exhibits an essential function in controlling the self-renewal of stem cells in various adult tissues, such as the skin, the hematopoietic system and the central nervous system. Interestingly, Activin/Nodal signalling could have complementary functions in self-renewal and differentiation of adult stem cells. Further investigations, including tissue-specific gene knockout for Nodal and the Inhibins, could help to further understand the specificity of each of these growth factors in organ homeostasis and tissue repair.

**Activin/Nodal signalling in cancer and metastasis**

Cancer stem cells (CSCs) can give rise to a new tumour that shows similar features to its parental tumour. CSCs have been identified in various cancer types, including pancreatic cancer, melanoma, glioma, chronic myeloid leukaemia and malignant squamous cell carcinoma (Chen et al., 2008; Driessens et al., 2012; Scheipers et al., 2012; Schober and Fuchs, 2011). A number of mutations leading to cancer affect genes involved in the Activin/Nodal/TGFβ signalling pathways, including ACVR1, TGFBR1/II, Smad2 and Smad4 (Massagué, 2008). These mutations tend to accumulate in tissue-specific stem cells due to their longevity (Lobo et al., 2007). Interestingly, the role of Activin/Nodal signalling in tumorigenesis and CSCs often reflects the function of this pathway in embryonic development or in adult tissue homeostasis. Indeed, the Activin/Nodal pathway regulates self-renewal and differentiation of CSCs, and increases the plasticity and metastatic potential of tumour cells (Lonardo et al., 2011; Spiller et al., 2012; Topczewska et al., 2006). Accordingly, the mutation of the Inhibin A subunit (an Activin inhibitor) in the mouse gonad results in stromal/granulosa tumour, suggesting that Activin signalling could be tumorigenic if not tightly controlled (Matzuk et al., 1992). Similarly, Nodal is expressed in a diversity of tumours, including melanoma, prostate, breast and testicular cancer (Hardy et al., 2010; Lawrence et al., 2011; Lonardo et al., 2011; Spiller et al., 2012; Strizzi et al., 2012; Topczewska et al., 2006), with the degree of tumour malignancy correlating with the amount of secreted Nodal (Spiller et al., 2012). In addition, the Nodal co-receptor Cripto is expressed in a diversity of tumours, including melanoma, prostate, breast and testicular cancer (Lonardo et al., 2011; Postovit et al., 2008).

In melanoma, Nodal signalling also promotes the vascularisation of the tissue surrounding the tumour, which might be responsible for the malignancy and high incidence of metastases due to increased invasiveness in these cancers (Hardy et al., 2010; Seftor et al., 2012). A similar vascularisation-promoting effect has been noted for breast cancers: Nodal signalling leads to the upregulation of pro-angiogenic factors in the tissue surrounding the tumour cells (Quail et al., 2013). Based on these observations, it is tempting to hypothesise that abnormally high activation of Nodal signalling in adult stem cells, combined with genetic mutations, could result in increased proliferation but also resistance to differentiation, thereby mimicking the mechanisms maintaining pluripotency of hPSCs. Future investigations including Smad2/3 ChIP-Seq and proteomic analyses in CSCs will be useful to compare the mechanisms involving Activin/Nodal signalling in self-renewal and differentiation during embryonic development and tumorigenesis.

**Cell cycle regulation**

TGFβ is a known cytostatic factor (which inhibits cell growth and proliferation) (Massagué, 2004): it regulates cell cycle progression in many cell types and acts as a central pathway for mediating cytostatic responses. In most cases, it triggers potent anti-proliferative effects by inducing the expression of cyclin-dependent kinase inhibitors (CDKIs) of the INK4 (p14, p15, p16, p18, p19) or KIP/CIP (p21, p27, p57) protein family (Massagué, 2008). These cell cycle inhibitors usually cause the cells to reversibly arrest in G1 phase, but they can also lead to terminal differentiation (Evans et al., 2003) or programmed cell death. Of note, this function of the TGFβ signalling pathway could be inhibited by SNON or SKI in hPSCs (Tsuneyoshi et al., 2012), as these genes are known to limit the transcriptional activity of Smad2/3 and especially to block induction of CDKIs such as p21 (Zhu et al., 2007). Importantly, Activins are known to control cell cycle by similar CDKI-dependent mechanisms (Chen et al., 2002), thereby suggesting an overlapping function between TGFβ and Activin signalling in proliferation control. Nodal function in cell cycle control remains to be fully investigated, especially as Nodal seems to potentiate the plasticity and metastatic capacity of CSCs.

The interplays between Activin/Nodal/TGFβ signalling and cell cycle regulations are certainly more complex, especially in the context of stem cells. Indeed, our group and others have shown that Activin signalling in hPSCs could be directly controlled by Cyclin D/CDK complexes, which can limit the shuttling of Smad2/3 into the nucleus. Thus, these cell cycle regulators restrain the inductive effects of Activin/Nodal signalling on endoderm differentiation (Pauklin and Vallier, 2013). This mechanism enables cell cycle-specific regulation of cell fate choice in hESCs. Endoderm differentiation can only be induced in early G1 phase, when Cyclin Ds are expressed at low levels, whereas neuroectoderm specification can only be induced in late G1 phase, when Cyclin Ds are highly expressed. These mechanisms could also be important for a number of somatic stem cells, as functional studies have demonstrated that loss of function of Cyclin D/CDK results in the lengthening of G1 phase in neuronal stem cells in vivo, while increasing their differentiation into neurons (Lange and Calegari, 2010; Lange et al., 2009). Similarly, absence of Cyclin Ds or CDK4/6 results in premature differentiation of hematopoietic stem cells (Lange and Calegari, 2010). Taken together, these studies highlight a complex relationship between cell cycle and Activin/Nodal/TGFβ signalling pathways, and how these mechanisms could be essential to synchronise proliferation and cell fate choice in stem cells.

In addition to TGFβ-mediated regulation of CDKIs, there is also evidence for TGFβ controlling cell cycle progression via other routes. Specifically, TGFβ can inhibit expression of c-myc and also relieve inhibition of Rb expression; both these activities would repress proliferation and promote differentiation. These observations underline once again the intrinsic relationship between cell cycle regulators and cell fate choice, and the essential role played by TGFβ, and potentially by Activin/Nodal, in this process. It would be tempting to suggest that aberrant regulations of these mechanisms could be part of the process leading to the emergence of CSCs. This hypothesis
could be explored further by studying the role of cell cycle-related factors in the inhibition of CSC differentiation.

**Perspectives**

Activin/Nodal signalling has been shown to control various mechanisms in different model organisms and in a diversity of cell types. The function of this pathway in pluripotent stem cells remains relatively recent and opens new perspectives to understand the cross-talk between cell cycle, cell fate decisions and epigenetic regulation. One can hypothesise that these mechanisms could be conserved in adult stem cells and ultimately constitute the central unit defining ‘stemness’. Indeed, Activin, Nodal or TGFβ growth factors are found in various tissues, and their activity is essential for a number of cell types. However, mechanistic insight on the function of these signalling molecules in self-renewal/cell fate decisions is still lacking. The technical challenge to perform tissue-specific genetic studies in animal models explains in part this situation. The importance of other signalling pathways such as WNT might have also obscured the role of Activin/Nodal/TGFβ in these mechanisms. Finally, the dominant function of TGFβ in cell cycle regulation might mask its role in regulating cell fate decisions in multipotent stem cells. Indeed, gain or loss of function of TGFβ signalling members often results in uncontrolled proliferation or quiescence, both of which indirectly affect cell fate decisions, thereby masking any potential role for these factors in differentiation. The availability of new culture systems to maintain somatic stem cells *in vitro*, such as the three-dimensional organoid approach (Sato and Clevers, 2013), combined with efficient genome-editing methods such as CRISPR (Cong et al., 2013; Mali et al., 2013), could provide new opportunities to delineate the contribution of Activin/Nodal/TGFβ in the self-renewal of adult stem cells and their differentiation toward functional cell types during organ homeostasis.

In parallel, hPSCs represent a unique opportunity to study the molecular mechanisms controlling Activin/Nodal functional activity and cellular specificity in self-renewal and differentiation. Indeed, the Activin/Nodal signalling pathway seems to be constantly controlling opposite cellular mechanisms, such as proliferation versus quiescence, self-renewal versus differentiation and tumorigenesis versus apoptosis. Furthermore, a large number of genes with apparently divergent functions have been identified as targets for Activin/Nodal-Smad2/3 signalling, for example *NANOG* (pluripotency) and *SOX17* (endoderm differentiation). Although this appeared initially counterintuitive, it is now evident that Activin/Nodal signalling activity is mediated by lineage-specific transcription factors that help targeting the Smad2/3 complex and co-regulator complexes to specific loci in a context-dependent manner. However, such models also raise questions concerning the molecular function of Smad2/3 in these protein complexes, which control conflicting aspects of cellular biology. Indeed, it remains to be uncovered whether the Smad2/3 complex is only necessary to build transcriptional complexes controlling the expression of different sets of genes or whether it has a more direct function by controlling the activity of key transcription factors and epigenetic modifiers. Furthermore, the number of Smad2/3 partners continues to increase, with very little overlap between different cell types. Proteome-wide analyses are yet to reveal the full list of Smad2/3 binding partners, and thus, the complexity and diversity of protein-protein interactions involving Smad2/3 are likely to be underestimated. Identification of Smad2/3 binding partners at various developmental stages and in stem cells will help to clarify why Smad2/3 has so many apparently distinct functions in different developmental contexts and how this diversity is mechanistically achieved.

To conclude, Activin/Nodal/TGFβ pathways function not only in cell fate choice during embryogenesis, but also in cell cycle regulation and adult tissue homeostasis. As cross-talk between cell cycle regulation, self-renewal and differentiation is essential for controlling the function of stem cells during development and in adult organs, the Activin/Nodal/TGFβ pathways might function as a direct link between these fundamental processes. Further research will be necessary to demonstrate the importance of these mechanisms in normal regenerative processes and in the formation of CSCs. Thus, a more complete picture of the mechanistic aspects of Activin/Nodal signalling in stem cells could help to develop new regenerative approaches and unveil novel therapeutic targets for the treatment of cancer.

**Competing interests**

The authors declare no competing or financial interests.

**Funding**

S.P. was supported by the EUFP7 grant InnovaLiV and an FEBS long-term fellowship. L.V. was supported by the ERC starting grant Relieve IMDS and the Cambridge Hospitals National Institute for Health Research Biomedical Research Centre.

**References**


